Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rongping Li

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Journal of Translational Medicine|January 22, 2025
Firsekibart in acute gouty arthritisYu Xue, Tianshu Chu, Jiankang Hu, et al.
Annals of Botany|May 27, 2026
Seed size coupled with environmental effects on the level of physiological dormancy in Acer mono from different geographic provenancesShitong Gao, Qiaoling Yan, Yuan Song, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Journal of Translational Medicine|January 22, 2025
Firsekibart in acute gouty arthritisYu Xue, Tianshu Chu, Jiankang Hu, et al.
Annals of Botany|May 27, 2026
Seed size coupled with environmental effects on the level of physiological dormancy in Acer mono from different geographic provenancesShitong Gao, Qiaoling Yan, Yuan Song, et al.
Rheumatology and Therapy|August 20, 2025
Efficacy and Safety of Firsekibart Compared to Etoricoxib for Gout Flares: A Phase 2, Multicenter, Open-label, Active-controlled, Randomized Non-inferiority TrialNing Kong, Yu Xue, Li Mao, et al.
Innovation (Cambridge (Mass.))|August 15, 2025
Firsekibart versus compound betamethasone in acute gout patients unsuitable for standard therapy: A randomized phase 3 trialYu Xue, Tianshu Chu, Jiankang Hu, et al.
Advances in Therapy|May 19, 2026
Efficacy and Safety of Firsekibart in Patients with Acute Gout Unsuitable for Standard Therapy: 48-Week Results from an Open-Label Extension of a Randomized Phase 3 TrialZaihua Zhu, Yu Xue, Tianshu Chu, et al.
Pageof 3